Subscribe to Updates

    Get the latest creative news from CRYPTO NOUNCE.

    What's Hot

    Ticketmaster sucks. Can blockchain be the cure?

    March 25, 2023

    Amid US banking crisis, GPT and NVIR top MEXC search results

    March 25, 2023

    Salesforce, Inc. (NYSE:CRM) Insider Sells $232,337.50 in Stock

    March 25, 2023
    Facebook Twitter Instagram
    Facebook Twitter Instagram Vimeo
    Cryptonounce.com
    Contact
    • Business
      • Deals
      • investors
      • IPO
      • Startups
      • Wall Street
    • Markets
      • Bonds
      • Commodities & Futures
      • Currencies
      • Funds & ETFs
      • Stocks
    • Crypto
      • Alticoins News
      • Binance News
      • Bitcoins News
      • Blockchain News
      • Ethereum News
      • Token Sales News
      • XRP News
    • Technology
      • Artificial Intelligence
      • Big Data
      • Cloud Computing
      • Cybersecurity
      • Gaming
      • Internet of Things
      • Mobile
      • Social Media
      • Transportation
      • VR & AR
    • FinTech
    • Personal finance
    • Grides
      • Crypto
      • FinTech
      • Investing
      • Personal Finance Guides
      • Techonology
    • Tools
      • Coins
      • ICO List
      • Organigations
      • Events
    Cryptonounce.com
    Home » Editas Medicine tumbles more than 7% after announcing job cuts, restructuring
    Markets

    Editas Medicine tumbles more than 7% after announcing job cuts, restructuring

    AdmincryptBy AdmincryptJanuary 9, 2023No Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email
    Share
    Facebook Twitter LinkedIn Pinterest Email


    Editas Medicine Inc. [s: edit] is cutting approximately 20% of its workforce. The company reported 1,800 employees as of May 31, according to its annual report. In a statement released Monday Editas said the move will extend its cash runway into 2025. Editas’ stock fell 7.7% Monday, compared with the S&P 500 Index’s [s: spx] gain of 1.3%. Editas said the cuts are part of a strategic reprioritization that includes focusing resources on EDIT-301, Editas’ clinical program for the treatment of severe sickle cell disease and transfusion-dependent beta thalassemia, a blood disorder that reduces production of hemoglobin. The gene editing company is also discontinuing internal investments in its inherited retinal disease programs and its wholly-owned multiplexed edited induced pluripotent stem cell derived natural killer cell programs. Additionally, Editas is restructuring its research organizations into two divisions and says it will continue advancing its cellular therapy assets through partnerships. This includes development of alpha-beta T-cell medicines with Bristol-Myers Squibb Co. [s: bmy] and gamma-delta T-cell medicines with Immatics N.V. [: imtx]. Editas also announced that Chief Scientific Officer Mark S. Shearman is stepping down from his role and will depart the company March 31. Editas has begun a search for a new CSO, the company said. 



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Previous ArticleBeazley’s cyber cat bond used Artex SAC vehicle & CyberCube model
    Next Article CARISSA RAE: How the Cookie Crumbles
    Admincrypt
    • Website

    Related Posts

    Salesforce, Inc. (NYSE:CRM) Insider Sells $232,337.50 in Stock

    March 25, 2023

    The biggest financial crises of the last four decades By Reuters

    March 25, 2023

    Merit Financial Group LLC Buys Shares of 5,590 General Mills, Inc. (NYSE:GIS)

    March 25, 2023

    General Mills, Inc. (NYSE:GIS) Shares Sold by First Hawaiian Bank

    March 25, 2023

    Leave A Reply Cancel Reply

    Our Picks
    • Facebook
    • Twitter
    • Pinterest
    • Instagram
    • YouTube
    • Vimeo
    Don't Miss
    Techonology

    Ticketmaster sucks. Can blockchain be the cure?

    By AdmincryptMarch 25, 20230

    Welcome to the TechCrunch Exchange, a weekly startups-and-markets newsletter. It’s inspired by the daily TechCrunch+…

    Amid US banking crisis, GPT and NVIR top MEXC search results

    March 25, 2023

    Salesforce, Inc. (NYSE:CRM) Insider Sells $232,337.50 in Stock

    March 25, 2023

    Learn to Build a ChatGPT Bot for Only $30

    March 25, 2023

    Subscribe to Updates

    Get the latest creative news from CRYPTO NOUNCE.

    NEWS
    • Business
    • Crypto
    • Blockchain
    • Markets
    • Technology
    FEATURED SECTIONS
    • Coins
    • ICO List
    • Organigations
    • Events
    • Grides
    FEATURED LINKS
    • Story of the day
    • Videos
    • Infographics
    CONNECT WITH US
    • Facebook
    • Twitter
    • Telegram
    • LinkedIn
    • Pinterest
    ABOUT US
    • Contact
    • Advertise
    • Sitemap
    Copyright © 2023 Cryptonounce All rights reserved. Cryptonounce.
    • Home
    • Buy Now

    Type above and press Enter to search. Press Esc to cancel.

    Sign In or Register

    Welcome Back!

    Login to your account below.

    Lost password?